Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2026 08:00 ET | Source: Filana Therapeutics, Inc.

Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data

Study in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufilam attenuated the progression of seizures in a dose-dependent mannerResults confirm and extend...
April 15, 2026 08:00 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). ...
April 15, 2026 07:52 ET | Source: ONTO Health

AI-Enabled Fertility Care and Longevity Provider ONTO Health Closes $20 Million Series funded by ARTIS and Humania

HEALTHCARE/AI FUNDING NEWS: ONTO Health, an AI-enabled, physician-led fertility and longevity provider, has announced the close of a $20 million Series.
April 15, 2026 07:30 ET | Source: Contura Orthopaedics Ltd

Inside the Science: New White Paper Explores the Injection Set to Redefine the Treatment of Knee Osteoarthritis & Unlock Access to Non-Surgical Options for Patients on the NHS

A new white paper has been released which heralds the dawn of a new era of treatment for knee osteoarthritis
April 15, 2026 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 ...
April 15, 2026 07:30 ET | Source: BrainsWay

BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy

BURLINGTON, Mass. and JERUSALEM, April 15, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
April 15, 2026 07:30 ET | Source: Arbutus Biopharma Corporation

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:...
April 15, 2026 07:00 ET | Source: Orvida Pharma Ltd

Orvida Pharma (formerly Kamari Pharma) Announces Favorable Phase 1a Safety Data for KM-023, a Potential First-in-Disease Oral TRPV3 Inhibitor, and Initiation of Phase 1b Study in Patients with Olmsted Syndrome

First Olmsted syndrome patient dosed in global Phase 1b study Company now operating under its new name, Orvida Pharma NESS ZIONA, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Orvida Pharma (formerly...
April 15, 2026 07:00 ET | Source: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development

TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime, is the first new FDA-approved treatment for fibromyalgia in adults in more than 15 years TONMYA commercially...
April 15, 2026 06:07 ET | Source: ALK Abello

neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Health Canada has approved neffy® 2 mg for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites,...